Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2012

View Archived Issues

New agent for liver disorders patented by Norgine Europe

First-in-class cancer immunotherapy well tolerated in phase I trial

Novel solute carrier family 22 member 12 inhibitors designed

Bristol-Myers Squibb presents novel HIV integrase inhibitors

Taiho Pharmaceutical reports new H-PGDS inhibitors

New protein kinase inhibitors disclosed by Bayer Schering Pharma

Cell-based gene therapy is well tolerated in phase I study

CSA-131 active against Gram-negative bacteria

ARMOR1 trial assesses safety of galeterone in prostate cancer

Amgen presents first preclinical data on novel anticancer drug

New data support potential of Cell-in-a-Box technology

Novel anticancer nanomedicine shows promise in clinical trial

DARPin-based VEGF inhibitor completes phase IIa trial

Muscular Dystrophy Association awards grant to Catabasis Pharmaceuticals

Sanofi and Alfresa Pharma launch vigabatrin collaboration

Stroke biomarker license granted to Randox

Spectrum Pharmaceuticals announces acquisition

Phase III results reported for apaziquone

Amorfix establishes proof of concept for lead tumor-specific antibody

FDA approves adjunct radioactive diagnostic for Alzheimer's disease

FDA advisory committee issues recommendation on Astellas' mirabegron

Preclinical studies demonstrate small molecule's efficacy to treat anterior uveitis

Phase I/II trial begins evaluating Syndax's entinostat with lapatinib in metastatic breast cancer

Winston Pharmaceuticals receives grant to develop civamide nasal solution

Pacira Pharmaceuticals launches Exparel in U.S.

Next-generation drug-eluting stent approved in Japan to treat coronary artery disease

Pharmos reports promising data from ongoing phase IIa trial of levotofisopam

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...